Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for ...

Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest's fibrinogen aims to fulfill a high unmet medical need for ...

Atara Biotherapeutics ATRA is a nimble allogeneic T cell immunotherapy company with several near-term catalysts. This Zacks ...

Intellia said the Phase 3 HAELO study evaluating NTLA-2002 for HAE to complete enrollment in the second half of 2025, and the company plans to ...

Capricor's biologics license application for deramiocel (CAP-1002) is draws largely on the Phase 2 HOPE-2 trial and its ...

A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets ...

A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.

Precigen, Inc. (NASDAQ:PGEN) shares are trading higher on Monday after the company completed the rolling submission for a ...

A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial ...

Established in 2022, the partnership is centred on the manufacturing of a cGMP 2000L drug substance commercially.

Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest's fibrinogen aims to fulfill a high unmet medical need for ...

Precigen, Inc. PGEN shares are trading higher on Monday after the company completed the rolling submission for a biologics license application to the FDA for PRGN-2012 (zopapogene imadenovec ...